Reducing Hf Hospitalization Risk: Antidiabetic Drug Classes Compared | Latest News RSS feed

Reducing Hf Hospitalization Risk: Antidiabetic Drug Classes Compared - Latest News


Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors appear to be more effective than glucagon-like peptide 1 (GLP-1) agonists or dipeptidyl peptidase 4 (DPP-4) inhibitors for lowering the risk of hosp... read more

Certain Patients with Type 2 Diabetes Less Likely to Suffer Heart Failure While Taking New Class of Antidiabetic Drug

Patients with diabetes also face a higher risk of recurrent heart failure, compared with people without diabetes. Food and Drug Administration ... individuals using certain classes of medications, and ... read more

No increased heart failure with incretin-based drugs

Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic ... read more

Looking for another news?


Lilly diabetes drug cuts heart failure death, hospitalization: study

ORLANDO – Eli Lilly's new diabetes drug Jardiance significantly ... reduced the combined risk of hospitalization for heart failure or death from heart failure by 39 percent, compared with a placebo wh... read more


Experimental cholesterol drugs cut heart risks, but questions remain

Studies of a new class of experimental cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack and other major cardiovascular problems compared ... unstable chest pain ... read more

Emerging Heart Failure Strategies Improve Outcomes and Reduce Readmissions

These patients want and need to avoid hospitalization ... Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physician... read more

Novartis' PARADIGM-HF study shows Entrest reduces cardiovascular death/hospitalization for heart failure patients with reduced ejection fraction

Novartis announced new analyses of the data from PARADIGM-HF ... compared to enalapril. Entresto is indicated in the US to reduce the risk of cardiovascular death and hospitalization for heart failure ... read more

FDA: Two diabetes drugs may be linked to heart failure risk

This means that 35 out of every 1,000 patients taking the drug were hospitalized for heart failure, compared with 28 out of every 1,000 patients not taking it. Risk ... Hospital in New York City. She ... read more

No increased risk of heart failure with incretin-based drugs

After previous reports of an association between this class of drug and the occurrence of adverse pancreatic events, concerns have also been raised about a potential increased risk ... risk of heart f... read more

Anthem : Certain Patients with Type 2 Diabetes Less Likely to Suffer Heart Failure While Taking New Class of Antidiabetic Drug

HealthCore study is the first to report a direct comparison of two new medication classes on risk of heart failure hospitalization ... inhibitor compared to dipeptidyl peptidase-4 (DPP4) inhibitors, a... read more

Novartis PARADIGM-HF phase III study of Entresto helps to preserve kidney function in heart failure patients with diabetes

Diabetes significantly increases an individual's risk for CKD. Added to this, many anti-diabetic ... class II-IV) in patients with systolic dysfunction. It has been shown to reduce the rate of cardiov... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us